{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-013406","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2022-07-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.900390+00:00","generated_at":"2026-06-24T07:01:19.212694+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Inhibikase receives Nasdaq notice for non-compliance with $1.00 minimum bid price rule","bullets":["Nasdaq notice dated July 25, 2022; stock bid price below $1.00 for 30 consecutive business days.","Company has 180 calendar days, until January 23, 2023, to regain compliance.","To cure, closing bid price must be at least $1.00 for 10 consecutive business days.","Failure may lead to a second 180-day cure period or delisting, subject to appeal."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-013406","json":"https://secwatch.observer/filing/0000950170-22-013406.json","markdown":"https://secwatch.observer/filing/0000950170-22-013406.md","text":"https://secwatch.observer/filing/0000950170-22-013406.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000095017022013406/0000950170-22-013406-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000095017022013406/ikt-20220725.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:01:19.212694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}